Best Practice Case Studies-Hodgkin Lymphoma

Pdf Summary

This review provides a comprehensive overview of Hodgkin Lymphoma (HL), discussing its pathogenesis, diagnosis, and treatment approaches for adult patients. HL is a rare lymphoma, primarily affecting young adults, with a secondary incidence peak in individuals over 60. Historically, HL treatment has greatly advanced, shifting from an incurable condition to one with an excellent prognosis; first-line treatments, which combine chemotherapy and/or radiotherapy, yield an 80% cure rate.<br /><br />HL treatment varies by stage and risk factors. Early favorable-stage HL typically requires two cycles of ABVD chemotherapy and radiotherapy. For early-stage unfavorable HL, four cycles of ABVD, possibly followed by radiation, are common, although more intense eBEACOPP chemotherapy may be used in some cases. Advanced-stage HL often necessitates more rigorous treatment; eBEACOPP is standard, though ABVD remains widespread due to its less intensive nature.<br /><br />Treatment strategies for relapsed or refractory HL typically involve a second line of salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant (ASCT). Recent treatments include Brentuximab Vedotin and checkpoint inhibitors like nivolumab and pembrolizumab, which have shown significant promise in clinical trials, especially in cases refractory to standard therapies.<br /><br />In terms of epidemiology, HL occurs in 2–3 individuals per 100,000 per year, with genetic factors, Epstein-Barr Virus, and HIV infection as notable risk aspects. Diagnosis and staging rely on various imaging techniques and histopathological analysis.<br /><br />Future approaches aim to incorporate less toxic, targeted treatments like novel immunotherapies earlier in treatment courses, potentially improving efficacy and minimizing long-term side effects. Research emphasis also includes optimizing treatment regimens for older populations, who often experience more aggressive disease forms and less favorable outcomes.

Meta Tag

Edition 3rd Edition

Related Case 3rd Edition, CASE 42

Topic Oncology

Keywords

3rd Edition, CASE 42

3rd Edition

Oncology

Hodgkin Lymphoma

pathogenesis

diagnosis

treatment

chemotherapy

radiotherapy

ABVD

eBEACOPP

Brentuximab Vedotin

checkpoint inhibitors